Patents by Inventor Masahira Hattori

Masahira Hattori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200093871
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 26, 2020
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Patent number: 10576136
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 3, 2020
    Assignees: Keio University, The University of Tokyo
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20200038459
    Abstract: The present invention provides a composition for preventing or treating a graft-versus-host disease, the composition comprising a fecal microbiota.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Kazuhiko Kakihana, Masahira HATTORI, Kenya HONDA, Hiroyoshi NISHIKAWA, Hidetoshi MORITA, Kozue TAKESHITA
  • Publication number: 20200017821
    Abstract: Provided are a functional microbial material and a method for producing a fermentation product, wherein the functional microbial material and the fermentation product are environment-friendly and improve the quality of crops. The present invention relates to a microbial material and a method for producing a fermentation product wherein the microbial material and the fermentation product are obtained by fermentation of a fermentation raw material including a plant-derived raw material and an animal-derived raw material using a population of microorganisms including a plurality of species of thermophilic microorganisms, and lead to a remedy for soil and water pollution and to the inhibition of greenhouse gas generation, as well as contribute to improvements in the functionality of plants, particularly the expression of genes involved in biophylaxis and resistant to high-temperature disorder, and an increase in antioxidant components.
    Type: Application
    Filed: July 25, 2019
    Publication date: January 16, 2020
    Inventors: Hirokuni Miyamoto, Kiroaki Kodama, Hisashi Miyamoto, Takumi Nishiuchi, Kazuto Ishikawa, Kazuo Ogawa, Toshiyuki Ito, Takuya KAMITAI, Kenshiro Oshima, Wataru Suda, Masahira Hattori
  • Publication number: 20190381111
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 19, 2019
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20190343944
    Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 14, 2019
    Inventors: Kenya Honda, Takeshi Tanoue, Masahira Hattori, Yutaka Kawakami
  • Publication number: 20190314426
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: May 31, 2019
    Publication date: October 17, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190290753
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Application
    Filed: April 5, 2019
    Publication date: September 26, 2019
    Applicants: Riken, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10342832
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 9, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10300137
    Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 28, 2019
    Assignees: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10238694
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: March 26, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190046591
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 14, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20190030092
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: October 15, 2018
    Publication date: January 31, 2019
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10183045
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 22, 2019
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20180243348
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20180245138
    Abstract: Provided is a diagnosis method for an autoimmune disease, including a step of measuring the relative abundances of bacteria included in a fecal sample collected from a test subject; and a step of performing the following (1), for example: (1) in a case in which relative abundance of a bacterium whose nucleotide sequence of 16S ribosomal RNA gene has an identity of 99% or higher with nucleotide sequence set forth in SEQ ID NO:3 or SEQ ID NO:4, is large compared to the relative abundance in healthy subject, determining that the test subject has contracted, or has a high risk of contracting, the autoimmune disease.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 30, 2018
    Inventors: Takashi YAMAMURA, Masahira HATTORI, Hidetoshi MORITA, Sachiko MIYAKE
  • Patent number: 10058578
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 28, 2018
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10052353
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: August 21, 2018
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institute
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20180185421
    Abstract: The present invention provides a composition for preventing or treating a graft-versus-host disease, the composition comprising a fecal microbiota.
    Type: Application
    Filed: August 28, 2017
    Publication date: July 5, 2018
    Inventors: Kazuhiko KAKIHANA, Masahira Hattori, Kenya Honda, Hiroyoshi Nishikawa, Hidetoshi Morita, Kozue Takeshita
  • Patent number: 9987312
    Abstract: To provide a mixture, a dissolving solution and a pharmaceutical agent, which contain a thermophilic microorganism to make it possible to regulate a mucous membrane immune system gene cluster and metabolism-related gene clusters of the intestines and the liver. Each of them is prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less. By being administered to the animal, it regulates at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines, and a metabolism-related gene cluster in the liver of the animal. The microorganism includes at least one species of the genus Bacillus, Oceanobacillus, Paenibacillus, Anoxybacillus, Lysinibacillus, Methanopyrus, Geogemma, Pyrolobus, Pyrodictium, Hyperthermus, Pyrococcus, Pyrobaculum, Thermococcus, Aeropyrum, Aquifex, Thermotoga, Thermodesulfobacterium, Thermus, Geobacillus, and Thermomyces.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: June 5, 2018
    Assignees: JAPAN ECO-SCIENCE CO., LTD., NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY, INDEPENDENT ADMINISTRATIVE INSTITUTION NATIONAL FISHERIES UNIVERSITY, MIROKU CO., LTD., KEIYO PLANT ENGINEERING CO., LTD.
    Inventors: Hirokuni Miyamoto, Hiroaki Kodama, Takumi Nishiuchi, Teruo Matsushita, Hisashi Miyamoto, Sankichi Horiuchi, Manami Seta, Kenichi Mori, Masahira Hattori, Kazuo Ogawa